NCT00404300终止3 期
An Open Multi-centre Study to Investigate the Safety and Efficacy of OPTIVATE®, a High Purity, Dual Inactivated Factor VIII and Von Willebrand Factor Concentrate, in Patients With Von Willebrand Disease Who Are Undergoing Surgery
Bio Products Laboratory8 个研究点 分布在 2 个国家目标入组 25 人开始时间: 2007年2月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- 入组人数
- 25
- 试验地点
- 8
- 主要终点
- A subjective overall assessment by the investigator of OPTIVATE® in the control of bleeding due to surgery throughout the whole study.
研究概览
简要总结
An open, multi-centre study in patients with von Willebrand Disease (VWD) undergoing surgery.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have given written informed consent.
- •Be aged 12 years or older.
- •Have VWD of known type.
- •Be due to undergo surgery, in which the investigator believes a VWF concentrate will be required.
- •Have a known lack of, poor response to, or contraindication to, DDAVP, or require a type of surgery in which a plasma-derived product is appropriate.
- •Have a prothrombin time (PT) of not more than 3 seconds above the upper limit of the reference range.
- •Female patients of child-bearing potential, with the exception of pregnant patients undergoing Caesarean surgery or other modes of delivery, including normal vaginal delivery, must have a negative result on a human chorionic gonadotropin-based pregnancy test. If a female patient is or becomes sexually active, she must practice contraception by using a method of proven reliability for the duration of the study.
排除标准
- •Have a history of inhibitor development to VWF or FVIII or a positive result at screening (positive screen for VWF inhibitor; positive screen and a result of >0.5 BU for FVIII inhibitor). A result at screening is not mandatory if the patient is to undergo emergency surgery and the local laboratory is unable to perform the analyses.
- •Patients with thrombocytopenia (platelets <50 x 109/L).
- •Patients who have clinically significant renal disease (creatinine >200 µmol/L).
- •Patients who have clinically significant liver disease (ALT levels greater than three times the upper limit of the reference range).
- •Presence of any other major systemic illnesses which would compromise the outcome of the study in the opinion of the investigator.
- •Known or suspected hypersensitivity to investigational medicinal product (IMP) or its excipients.
- •Have a recent history of alcohol or drug abuse.
- •Administration of a new chemical entity within the 4 months preceding enrolment.
- •Participation in any other clinical study in which investigational or marketed drugs were employed in the 30 days preceding enrolment (screening visit) into this study, with the exception of the BPL clinical study Protocol 8VWF
- •Female patients who are lactating.
- •In the opinion of the investigator, the patient is unlikely to comply with the study protocol.
结局指标
主要结局
A subjective overall assessment by the investigator of OPTIVATE® in the control of bleeding due to surgery throughout the whole study.
时间窗: Throughout the whole study
次要结局
未报告次要终点
研究者
研究点 (8)
Loading locations...
相似试验
已完成
4 期
A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow ResponseHepatitis C, ChronicNCT01033448Hoffmann-La Roche59
已完成
3 期
Study of Biostate® in Children With Hemophilia AHemophilia ANCT01229007CSL Behring35
已完成
不适用
A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary HypertensionPortopulmonary HypertensionPulmonary Arterial HypertensionPulmonary HypertensionNCT01028651United Therapeutics13
已完成
3 期
EASSI - Evaluation of the Safety of Self-Administration With IcatibantHereditary AngioedemaNCT00997204Shire151
已完成
3 期
CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe PruritusUremic PruritusNCT03998163Cara Therapeutics, Inc.222